Tissue repair, tendons and gut lining — and how thin the human evidence still is.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
Approved in 35 countries, 11,000 subjects, 30 trials. Then its largest randomised trial found nothing — and a meta-analysis showed exactly where the apparent benefit had been coming from.
KPV has the most specific mechanism of anything in this section, and a delivery route that inflamed tissue upregulates on its own. It is also there to fix a problem the blend creates.
Each component's evidence stops somewhere different. The claim that they combine well has no study behind it at all — and the best-supported benefit of blending is tolerability, not healing.
Randomised human evidence, a cosmetic shelf position, and an FDA restriction all attach to the same molecule — depending on the route. The clinical results quoted for the injection came from the topical.
The number every dosing schedule is built on has no published source. And the cancer reassurance that works for BPC-157 does not transfer to this one.
A 2025 review found 36 studies in sports medicine — 35 preclinical, one in humans. The mechanism is detailed and coherent. The human evidence is three small pilots and a cancelled trial.
